ClinicalTrials.gg
Active, not recruitingNCT04002297MANGROVEUpdated Sep 30, 2026

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

A Phase 3 interventional study of zanubrutinib and bendamustine in Mantle Cell Lymphoma; Non-Hodgkin Lymphoma, sponsored by BeOne Medicines. Active, not recruiting at 176 sites in 22 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by BeOne Medicines · Phase 3, Interventional, and Treatment

Updated Sep 30, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing zanubrutinib in Lymphoma, Mantle-Cell — 12 open to participants now, 14 under way, 2 of them phase 3. zanubrutinib · Lymphoma, Mantle-Cell.

Enrollment
Largest of 17
510 · median 45
Started
2019
with 1 other
Phase 3
2 of 17
1 open now
Primary completion
2026-04
later than 3 of 13 live
Registered
2nd of 17
by date
Lead sponsor
1 of 17
BeOne Medicines

Among the 17 studies testing zanubrutinib in Lymphoma, Mantle-Cell, this one has the largest enrollment, is one of 2 that started in 2019, is one of 2 in phase 3, reaches primary completion later than 3 of the 13 other live ones, and was the 2nd registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

12 of the 17 studies testing zanubrutinib in Lymphoma, Mantle-Cell are open now, in 4 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About zanubrutinib

zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing zanubrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

Read the detailed description

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

03

Conditions studied

  • Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Keywords

  • MCL, NHL, BTKi
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. ≥70 years of age at the time of , OR ≥60 and \<70 years of age with comorbidities precluding stem cell transplantation
  2. confirmed diagnosis of MCL
  3. No prior systemic treatments for MCL
  4. by CT/MRI
  5. (ECOG) performance status of 0-2
  6. Adequate marrow and organ function

Key Exclusion Criteria:

  1. Known central nervous system involvement by lymphoma
  2. Participants for whom the goal of therapy is tumor debulking prior to stem cell transplant
  3. cardiovascular disease
  4. History of severe bleeding disorder
  5. Unable to swallow capsules or disease significantly affecting gastrointestinal function
  6. Active fungal, bacterial and/or viral infection requiring systemic therapy
  7. Requires ongoing treatment with a strong inhibitor or inducer

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
510 participants (actual)

Study arms

  • Experimental
    Arm A: zanubrutinib plus rituximab

    Participants will receive zanubrutinib plus rituximab, followed by zanubrutinib monotherapy until Independent Review Committee (IRC)-confirmed disease progression.

    Drug: zanubrutinib · Drug: rituximab

  • Active comparator
    Arm B: bendamustine plus rituximab

    Participants will receive bendamustine plus rituximab, followed by observation.

    Drug: bendamustine · Drug: rituximab

Interventions

  • Administered as two 80 mg capsules by mouth twice a day

    Also known as: BGB-3111, Brukinsa

  • Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6

  • Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) determined by independent central review

    PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first.

    Time frame: Up to approximately 7 years

Secondary outcomes

  1. PFS by investigator assessment

    PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first.

    Time frame: Up to approximately 7 years

  2. Overall response rate (ORR)

    ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR), determined by independent central review and by investigator assessment.

    Time frame: Up to approximately 7 years

  3. Duration of response (DOR)

    DOR, as determined by independent central review and by investigator assessment, and defined as the time from the date that response criteria are first met to the date that disease progression is objectively documented or death, whichever occurs first.

    Time frame: Up to approximately 7 years

  4. Overall survival (OS)

    OS is defined as the time from randomization to the date of death due to any reason.

    Time frame: Up to approximately 7 years

  5. Time to Response (TTR)

    TTR, as determined by independent central review and by investigator assessment, and defined as the time from randomization to the first documentation of response.

    Time frame: Up to approximately 7 years

  6. Rate of complete response (CR) or complete metabolic response

    Rate of CR or complete metabolic response is defined as the percentage of participants who achieve a CR or complete metabolic response, determined by independent central review and by investigator assessment.

    Time frame: Up to approximately 7 years

  7. Participant-reported outcomes (PROs) as assessed by the European Quality of Life 5-Dimension 5 Level Questionnaire (EQ-5D-5L)

    EuroQoL-Five Dimensions, Five Levels (EQ-5D-5L) is a generic, self-reported measure of utility that consists of a five-item descriptive system and a visual analogue scale (EQ VAS). The descriptive system involves five health dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Participants may choose from the following response levels: no problems=1; slight problems=2; moderate problems=3; severe problems=4; and unable to/extreme problems=5. Higher values indicate worst health.

    Time frame: Up to approximately 7 years

  8. PROs as assessed by the European Organization for Research on Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best).

    Time frame: Up to approximately 7 years

  9. Number of participants with adverse events and serious adverse events

    Number of participants with adverse events and serious adverse events, including laboratory values, vital signs, and physical examination findings.

    Time frame: Up to approximately 7 years

07

Study locations

176 sites

Showing the first 100 of 176 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Dreyling M, Tam CS, Wang M, Smith SD, Ladetto M, Huang H, Novotny W, Co M, Romano A, Holmgren E, Huang J, Gouill SL. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncol. 2021 Jan;17(3):255-262. doi: 10.2217/fon-2020-0794. Epub 2020 Sep 28. PubMed 32985902 ↗

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Apr 2026, 80 months.

Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's 80 months is below that.

Primary completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Apr 2026, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2019
First posted
Jun 28, 2019
StartActual
Aug 20, 2019
Primary completionActual
Apr 27, 2026was Mar 2027
CompletionEst.
Sep 30, 2031
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2027→Apr 27, 2026 (actual)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Primary completion Mar 2027→Apr 27, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04002297
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Jun 28, 2019
Start date
Aug 20, 2019
Primary completion
Apr 27, 2026
Completion
Sep 30, 2031 (estimated)
Last update
Sep 30, 2026

Study contacts

Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion